BioSeek Achieves Milestone in Collaboration With Dynavax
Wednesday March 2, 8:00 am ET
- BioMAP(R) Systems Used to Characterize Novel Compound Activities -
BURLINGAME, Calif., March 2 /PRNewswire/ -- BioSeek, Inc. today announced that it has achieved a key milestone in its previously announced development collaboration with Dynavax Technologies Corporation (Nasdaq: DVAX - News), and has received a milestone payment from Dynavax, a biotechnology company focused on products to treat and prevent allergies, infectious diseases, cancer and chronic inflammatory diseases.
In the collaboration, BioSeek has used its proprietary BioMAP® Systems to characterize the biological activity of a novel family of TNF-alpha inhibitors known as thiazolopyrimidines (or TZPs). Dynavax is conducting research on orally available small molecules in this compound class for potential treatment of chronic inflammatory diseases. Under the terms of the agreement, BioSeek is eligible for additional milestone payments and royalties on future product sales. Financial terms were not disclosed.
"Our success in reaching this milestone demonstrates the ability of our BioMAP Systems to define mechanisms of action of novel drug candidates in the context of complex human disease biology," commented Peter D. Staple, chief executive officer of BioSeek. "We are pleased that we have been able to contribute to understanding the function and potential therapeutic utility of these compounds for Dynavax."
"BioSeek has provided us with important insights into the activity of our compounds," said Robert L. Coffman, Ph.D., vice president and chief scientific officer, Dynavax. "We are impressed with the disease-relevant information generated, relating to mechanism of action, and the quality of interaction with the BioSeek team."
About BioMAP® Systems
BioMAP Systems are primary human cell-based assay systems engineered to capture the complexity of human disease biology. In each System, combinations of human primary cells are activated in complex environments, replicating intricate cell and pathway interactions found in human physiology. Depending on their mechanism of action, compounds induce specific changes in the expression of protein readouts, producing a BioMAP profile. New BioMAP profiles are benchmarked against a large number of reference profiles in BioSeek's database using proprietary algorithms to characterize drug function, including mechanism of action and secondary or off-target activities, and to provide insights into clinical applications. This drug discovery platform can detect and distinguish a broad range of mechanistically diverse compound classes, enabling rapid identification of lead compounds with activities that are most relevant for developing safe, effective therapeutics.
About BioSeek
BioSeek uses its proprietary BioMAP® systems biology platform to discover and develop drug candidates based on their performance in complex human biology environments. With this technology, BioSeek has generated several internal small-molecule development programs for treatment of inflammatory diseases, and is identifying and accelerating development of promising new therapeutics for biotechnology and pharmaceutical company partners. For more information, go to www.bioseekinc.com.
and some background......
pubs.acs.org |
